TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis

被引：0

作者：

Harrold, Leslie ^{[1
,2
]}

Reed, George W. ^{[1
,2
]}

Boytsov, Natalie ^{[3
]}

Gaich, Carol L. ^{[3
]}

Mason, Marc ^{[2
]}

Zhang, Xiang ^{[3
]}

Larmore, Cynthia J. ^{[3
]}

Deveikis, Sabrina ^{[2
]}

Araujo, Andre B. ^{[3
]}

机构：

[1] Univ Massachusetts, Sch Med, Worcester, MA USA

[2] Corrona LLC, Southborough, MA USA

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1637

引用

页数：2

共 50 条

[1] PERSISTENCE ON TUMOUR NECROSIS FACTOR INHIBITOR (TNFI) MONOTHERAPY AFTER ACHIEVING REMISSION OR LOW DISEASE ACTIVITY (LDA) ON COMBINATION THERAPY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Pappas, D. A.
Litman, H. J.
Lesperance, T.
Rebello, S.
Karis, E.
Kricorian, G.
Hua, W.
Accortt, N.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 600 - 601
[2] Persistence of disease activity in patients with rheumatoid arthritis whose therapy remained unchanged for up to 18 months
Harrison, M. J.
Gibofsky, A.
Keystone, E.
Chon, Y.
White, B.
Louie, J.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 172 - 172
[3] Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Lau, Arthur
Movahedi, Mohammad
Tatangelo, Mark
Bombardier, Claire
JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1245 - 1246
[4] Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Lau, Arthur
Movahedi, Mohammad
Tatangelo, Mark
Bombardier, Claire
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[5] Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase
van Ingen, Iris L. A.
Lamers-Karnebeek, Femke
Jansen, Tim L.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (12) : 1761 - 1767
[6] DISCONTINUATION AND SWITCHING PATTERNS OF TUMOUR NECROSIS FACTOR INHIBITOR (TNFI) THERAPY IN TNFI-NAIVE AND TNFI-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS IN THE US CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
Mease, P.
Liu, M.
Gershenson, B.
Hur, P.
Greenberg, J.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 382 - 382
[7] PERSISTENCE WITH BIOLOGIC MONOTHERAPY IN COMPARISON WITH COMBINATION THERAPY WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS; RESULTS FROM AN ONTARIO RHEUMATOID ARTHRITIS COHORT
Lau, A. N.
Movahedi, M.
Tatengelo, M.
Bombardier, C.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 486 - 487
[8] The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis
Mirpourian, Maryam
Salesi, Mansour
Abdolahi, Hadi
Farajzadegan, Ziba
Karimzadeh, Hadi
JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 (06): : 509 - 514
[9] TNF inhibitors (TNFi): Useful additional therapy to methotrexate (MTX) in rheumatoid arthritis patients with severe disease.
Yazici, Yusuf
Yazici, Hasan
ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S246 - S247
[10] Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR's RISE Registry
Gianfrancesco, Milena
Li, Jing
Ja, Clairissa
Seet, Andrea
Schmajuk, Gabriela
Yazdany, Jinoos
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1193 - 1194

← 1 2 3 4 5 →